CKW Financial Group Has $93,000 Holdings in Eli Lilly And Co (LLY)

CKW Financial Group lessened its holdings in Eli Lilly And Co (NYSE:LLY) by 20.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 800 shares of the company’s stock after selling 200 shares during the period. CKW Financial Group’s holdings in Eli Lilly And Co were worth $93,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Carroll Financial Associates Inc. increased its position in shares of Eli Lilly And Co by 1.3% in the fourth quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock worth $810,000 after purchasing an additional 91 shares during the period. Northside Capital Management LLC lifted its stake in shares of Eli Lilly And Co by 0.7% in the fourth quarter. Northside Capital Management LLC now owns 17,403 shares of the company’s stock worth $2,014,000 after acquiring an additional 129 shares during the period. Cornerstone Advisors Inc. lifted its stake in shares of Eli Lilly And Co by 21.3% in the third quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock worth $83,000 after acquiring an additional 136 shares during the period. Cozad Asset Management Inc. lifted its stake in shares of Eli Lilly And Co by 6.8% in the fourth quarter. Cozad Asset Management Inc. now owns 2,493 shares of the company’s stock worth $288,000 after acquiring an additional 159 shares during the period. Finally, MPS Loria Financial Planners LLC lifted its stake in shares of Eli Lilly And Co by 9.1% in the fourth quarter. MPS Loria Financial Planners LLC now owns 2,046 shares of the company’s stock worth $236,000 after acquiring an additional 170 shares during the period. 77.00% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the company. Zacks Investment Research reaffirmed a “hold” rating and issued a $120.00 price objective on shares of Eli Lilly And Co in a research note on Monday, December 31st. Argus reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research note on Thursday, December 27th. BMO Capital Markets lifted their target price on Eli Lilly And Co from $124.00 to $132.00 and gave the stock an “outperform” rating in a report on Monday, December 24th. They noted that the move was a valuation call. Morgan Stanley set a $116.00 target price on Eli Lilly And Co and gave the stock a “hold” rating in a report on Thursday, December 20th. Finally, Citigroup downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 target price for the company. in a report on Sunday, December 2nd. Ten investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $111.50.

In other news, major shareholder Eli & Co Lilly sold 700,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total transaction of $9,800,000.00. Following the completion of the sale, the insider now owns 3,148,647 shares in the company, valued at $44,081,058. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 202,540 shares of the business’s stock in a transaction that occurred on Monday, November 12th. The shares were sold at an average price of $113.48, for a total value of $22,984,239.20. Following the sale, the insider now owns 118,814,164 shares of the company’s stock, valued at approximately $13,483,031,330.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,579,806 shares of company stock valued at $110,738,418. Corporate insiders own 0.11% of the company’s stock.

NYSE LLY opened at $119.16 on Friday. The company has a market cap of $123.73 billion, a PE ratio of 27.84, a PEG ratio of 1.78 and a beta of 0.33. Eli Lilly And Co has a 52 week low of $73.69 and a 52 week high of $119.84. The company has a quick ratio of 1.53, a current ratio of 1.91 and a debt-to-equity ratio of 0.83.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The company’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.05 earnings per share. On average, equities analysts anticipate that Eli Lilly And Co will post 5.58 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a dividend of $0.645 per share. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date is Thursday, February 14th. This represents a $2.58 annualized dividend and a dividend yield of 2.17%. Eli Lilly And Co’s payout ratio is currently 52.57%.

TRADEMARK VIOLATION NOTICE: This article was originally posted by WKRB News and is the property of of WKRB News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.wkrb13.com/2019/01/18/ckw-financial-group-has-93000-holdings-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: How does the Federal Reserve determine interest rates?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply